EP2791332A1 - Fungal strains with genetic modification relating to a carboxylic acid transporter - Google Patents
Fungal strains with genetic modification relating to a carboxylic acid transporterInfo
- Publication number
- EP2791332A1 EP2791332A1 EP12808323.5A EP12808323A EP2791332A1 EP 2791332 A1 EP2791332 A1 EP 2791332A1 EP 12808323 A EP12808323 A EP 12808323A EP 2791332 A1 EP2791332 A1 EP 2791332A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- strain
- carboxylic acid
- activity
- fungal
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002538 fungal effect Effects 0.000 title claims abstract description 26
- 238000012239 gene modification Methods 0.000 title claims abstract description 11
- 230000005017 genetic modification Effects 0.000 title claims abstract description 11
- 235000013617 genetically modified food Nutrition 0.000 title claims abstract description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 55
- 238000004519 manufacturing process Methods 0.000 claims abstract description 37
- 230000009467 reduction Effects 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 108010078791 Carrier Proteins Proteins 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 40
- 238000012217 deletion Methods 0.000 claims description 31
- 230000037430 deletion Effects 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 241000235015 Yarrowia lipolytica Species 0.000 claims description 27
- 150000001735 carboxylic acids Chemical class 0.000 claims description 22
- 241000233866 Fungi Species 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 15
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 claims description 13
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 10
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 9
- 102000019259 Succinate Dehydrogenase Human genes 0.000 claims description 9
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 101100354855 Homo sapiens PYDC1 gene Proteins 0.000 claims description 6
- 101710122479 Isocitrate lyase 1 Proteins 0.000 claims description 6
- 101150010895 PYC1 gene Proteins 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 241000235648 Pichia Species 0.000 claims description 5
- 241000235013 Yarrowia Species 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 4
- 241000235349 Ascomycota Species 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000235649 Kluyveromyces Species 0.000 claims description 3
- 241000235172 Bullera Species 0.000 claims description 2
- 241001527609 Cryptococcus Species 0.000 claims description 2
- 241001149669 Hanseniaspora Species 0.000 claims description 2
- 241001099157 Komagataella Species 0.000 claims description 2
- 241001304304 Kuraishia Species 0.000 claims description 2
- 241001123674 Metschnikowia Species 0.000 claims description 2
- 241001099335 Nakazawaea Species 0.000 claims description 2
- 241001112159 Ogataea Species 0.000 claims description 2
- 241000228143 Penicillium Species 0.000 claims description 2
- 241000893045 Pseudozyma Species 0.000 claims description 2
- 241000235527 Rhizopus Species 0.000 claims description 2
- 241000223252 Rhodotorula Species 0.000 claims description 2
- 241001489223 Saccharomycodes Species 0.000 claims description 2
- 241000235003 Saccharomycopsis Species 0.000 claims description 2
- 241000235346 Schizosaccharomyces Species 0.000 claims description 2
- 241000235006 Torulaspora Species 0.000 claims description 2
- 241000223259 Trichoderma Species 0.000 claims description 2
- 241000223230 Trichosporon Species 0.000 claims description 2
- 241000193620 Wickerhamia Species 0.000 claims description 2
- 241000235017 Zygosaccharomyces Species 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 2
- 241000235152 Williopsis Species 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 53
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 45
- 239000002609 medium Substances 0.000 description 32
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 30
- 229940049920 malate Drugs 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 20
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 20
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 18
- 230000010354 integration Effects 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 229940035893 uracil Drugs 0.000 description 15
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 14
- 101150050575 URA3 gene Proteins 0.000 description 14
- 235000005985 organic acids Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000004255 ion exchange chromatography Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 150000007524 organic acids Chemical class 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- -1 for example Chemical class 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 6
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 6
- 108010036781 Fumarate Hydratase Proteins 0.000 description 5
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 description 5
- 241001138401 Kluyveromyces lactis Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000013587 production medium Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- ACIOXMJZEFKYHZ-BXKDBHETSA-N (6r,7r)-7-amino-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)N)CC=1C[N+]1=CC=CC=C1 ACIOXMJZEFKYHZ-BXKDBHETSA-N 0.000 description 4
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 4
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 4
- 102100039892 Pyrin domain-containing protein 1 Human genes 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 3
- 101100170365 Arabidopsis thaliana At5g60805 gene Proteins 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 235000011960 Brassica ruvo Nutrition 0.000 description 3
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 3
- 102000006732 Citrate synthase Human genes 0.000 description 3
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 description 3
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 3
- 101150002475 mae1 gene Proteins 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 102100021198 Chemerin-like receptor 2 Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000750094 Homo sapiens Chemerin-like receptor 2 Proteins 0.000 description 2
- 101001033820 Homo sapiens Malate dehydrogenase, mitochondrial Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 102100035726 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000003673 Symporters Human genes 0.000 description 2
- 108090000088 Symporters Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000019113 chromatin silencing Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150024821 tetO gene Proteins 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000012033 transcriptional gene silencing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- YCHFCKWRGIPCMO-UHFFFAOYSA-N 2-(phenylhydrazinylidene)acetic acid Chemical compound OC(=O)C=NNC1=CC=CC=C1 YCHFCKWRGIPCMO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- 101100119887 Arabidopsis thaliana FDM1 gene Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000040382 Desulfofaba hansenii Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001465328 Eremothecium gossypii Species 0.000 description 1
- UTPGJEROJZHISI-DFGCRIRUSA-N Gaillardin Chemical compound C1=C(C)[C@H]2[C@@H](OC(=O)C)C[C@@](C)(O)[C@@H]2C[C@@H]2C(=C)C(=O)O[C@H]21 UTPGJEROJZHISI-DFGCRIRUSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000799318 Homo sapiens Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 description 1
- 101100438086 Homo sapiens SDHC gene Proteins 0.000 description 1
- 101150004970 IDP1 gene Proteins 0.000 description 1
- 102000004901 Iron regulatory protein 1 Human genes 0.000 description 1
- 108090001025 Iron regulatory protein 1 Proteins 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- 229910009891 LiAc Inorganic materials 0.000 description 1
- 108020004687 Malate Synthase Proteins 0.000 description 1
- 102100039742 Malate dehydrogenase, mitochondrial Human genes 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100031238 Mitochondrial dicarboxylate carrier Human genes 0.000 description 1
- 101710126521 Mitochondrial dicarboxylate carrier Proteins 0.000 description 1
- 101100409482 Neosartorya fumigata mcsA gene Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- UTPGJEROJZHISI-UHFFFAOYSA-N Pleniradin-acetat Natural products C1=C(C)C2C(OC(=O)C)CC(C)(O)C2CC2C(=C)C(=O)OC21 UTPGJEROJZHISI-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 101150040884 SDH3 gene Proteins 0.000 description 1
- 101150101425 SDH4 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 102000037089 Uniporters Human genes 0.000 description 1
- 108091006293 Uniporters Proteins 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 241000029538 [Mannheimia] succiniciproducens Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 238000013452 biotechnological production Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 101150091051 cit-1 gene Proteins 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 101150006726 icl gene Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 101150114996 sdhd gene Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/46—Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/50—Polycarboxylic acids having keto groups, e.g. 2-ketoglutaric acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
Definitions
- the present invention relates to fungal strains with genetic modification relating to a carboxylic acid transporter, and to processes for producing or using such fungi.
- carboxylic acids such as the Citrate cycle
- Citrate cycle a potential intermediate source material and as an alternative to petrochemical production processes in industry
- Many of these carboxylic acids have the potential to act as a so-called building block chemical.
- Important precursors for chemical synthesis, polyester production and other processes can be formed from said carboxylic acids.
- succinate is still mainly obtained petrochemically from maleic anhydride starting from butane.
- the petrochemical production of succinate using heavy metal catalysts, organic solvents, high temperatures and pressures is costly.
- Carboxylic acids such as succinate are naturally produced by many microorganisms, plants and animals as an intermediate in the central metabolism or as a metabolic end product.
- the majority of natural and optimized producers are bacterial strains that accumulate, for example, succinate, especially under anaerobic conditions. Due to the disadvantages of bacterial production methods, such.
- microbial fungi are increasingly becoming the focus of research into the development of processes for the production of organic acids such as succinate.
- US20110104771 discloses that a S. cerevisiae strain with an ICL gene from K. lactis, the malate synthase gene from S. cerevisiae, with a gene for PEPCK from M. succiniciproducens, the gene MDH2 from S. cerevisiae and with genes for fumarase ( from Rhizopus oryzae) and fumarate reductase (from Trypanosoma brucei) can produce up to 6.3 g of L "1 succinate after 7 days.
- Another object of the invention is to provide processes or organisms for the production of organic acids which have advantages over the bacterial processes.
- a fungal strain having a genetic modification that results in a reduction in the activity of at least one fungal carboxylic acid transporter.
- the carboxylic acid transporter in question is a membrane transport protein capable of transporting carboxylic acids through the cell membrane and possibly the cell wall.
- These are preferably transporters for dicarboxylic acids, preferably transporters for carboxylic acids of the citrate cycle or neighboring metabolic pathways.
- These may be symporters (co-transporters), but also uniporter or antiporter, most preferably transporters for at least one organic acid selected from the group comprising fumarate, lactate, pyruvate, malate, malonate and / or succinate.
- the term "targeting” is intended to clarify that said carboxylic acid transporter is encoded in the genome of the fungus.
- the term “homologous” may also be used. It is particularly preferred that said fungus has increased extracellular carboxylic acid production.
- carboxylic acids as used herein is identical to the term “organic acids” and refers to all those metabolic products of said fungus which may be referred to as carboxylic acids.
- the term preferably denotes the carboxylic acids of the citrate cycle and of neighboring metabolic pathways, in particular pyruvate, ⁇ -ketoglutarate, Malate, oxaloacetate, citrate, isocitrate, fumarate, malonate, lactate and / or succinate. Most of these acids are dicarboxylic acids.
- the reduction of the activity of the carboxylic acid transporter is achieved by at least one property or a step selected from the group comprising: a) inhibiting or reducing the expression of a gene coding for a carboxylic acid transporter
- Inhibition or reduction of expression may be accomplished, for example, by inhibiting or reducing transcription of the coding gene or translation of the generated mRNA.
- Expression of a dysfunctional or depressed active carboxylic acid transporter can be accomplished, for example, by deletion, insertion, substitution or point mutation in the coding gene.
- gene silencing In gene silencing, gene regulation takes place by inhibiting the transfer (transcription) of genetic information from the DNA to the mRNA (transcriptional gene silencing) or the subsequent translation (translation) of the mRNA stored information into a protein (post-transcriptional gene silencing).
- Transcriptional gene silencing is a result of epigenetic changes in DNA, such as DNA methylation or histone modifications in particular. These modifications of the histone ends create a kind of heterochromatic state around the gene which prevents it from binding to the transcription engine (RNA polymerase, transcription factors, etc.).
- the classic example is the phenomenon called position effect variegation (PEV). It alters the chromatin state and thus controls the transcriptional activity of the gene or gene region concerned.
- PEV position effect variegation
- Post-transcriptional gene silencing refers to the processes of gene silencing that occur only after the transcription of the genetic information from the DNA to the transmitting mRNA.
- forms of post-transcriptional gene silencing include, in particular, nonsense-mediated mRNA decay (NMD) and RNA interference (RNAi). While nonsense-mediated mRNA decay serves primarily to prevent nonsense point mutations, RNA interference is a predominantly regulatory process involving specific RNA molecules, such as miRNA and siRNA.
- Post-transcriptional gene silencing can result in increased degradation of the mRNA of a particular gene. The degradation of the mRNA prevents translation and thus the formation of the specific gene product (usually a protein).
- Gene knockout is understood to mean the complete shutdown of a gene in the genome of an organism. Switching off the gene is achieved by gene targeting.
- a deletion also gene deletion, in genetics is a variant of the gene mutation or in which a nucleotide sequence or a part up to the entire chromosome is missing. A deletion is therefore always a loss of genetic material. Any number of nucleobases may be deleted, from a single base (point mutation) to the chromosome. A distinction is made between the interstitial and the terminal deletion. The former describes a loss within the chromosome, the latter a loss of an end portion, ie a part of the telomeric region.
- deletion after translation, the mRNA produced from the DNA can be transformed create a faulty protein. Because deletion of base pairs can cause a frame shift mutation if a number of base pairs that are not divisible by three are removed. In site-specific or targeted mutagenesis, a targeted modification of the DNA is made possible by means of a recombinant DNA. It can be used to selectively exchange individual nucleobases of a gene or whole genes are removed. Alternatively, by means of a deletion cassette that has been integrated into a vector, a deletion can be generated in the gene to be mutated.
- the inhibition or reduction of expression of a gene may be by cloning a heterologous promoter which is inhibitable by an exogenous factor, for example a tetracycline-regulated tetO promoter.
- the inhibition or reduction of the expression of a gene can be carried out by cloning a heterologous promoter which is weaker than the relevant homologous promoter, for example pPOT1.
- the inhibition or reduction of the activity of the expressed carboxylic acid transporter may be accomplished, for example, by the administration of inhibitors or the synchronous expression of suitable heterologous inhibitors.
- the said fungus strain is preferably a strain of microbial fungi.
- microbial fungus as used herein is intended to include in particular those fungi which can be cultured by biotechnological methods and are particularly suitable for fermentative production processes, for example in suspension cultures.
- the fungus is a member of the group of ascomycetes (Ascomycota). Particularly preferably, it is a member of the group of Hemiascomycetes or Euascomycetes. In a further preferred embodiment, said fungal strain is um a yeast or a mold.
- Saccharomyces Saccharomyces
- Schizosaccharomyces Wickerhamia
- the at least one carboxylic acid transporter originates from the group of the JEN transporters and / or the MAE transporters.
- JEN orthologues of the K. lactis genes KlJEN1 and KUEN2 have been found in 17 different species of fungi (13 hemiascomycetes, 7 euassomycetes).
- the number of JEN orthologues varies from one (eg, BS cerevisiae) to six orthologous genes in Y. lipolytica.
- the following table provides an overview of the group of JEN transporters, as well as, in the last few lines, the known MAE transporters:
- Type Type Work name EMBL Swiss-Prot Length Number of
- the at least one carboxylic acid transporter originates from the group of JEN transporters and / or MAE transporters listed in the following table.
- the gene in question was deleted by means of a deletion cassette integrated in a vector (SEQ ID Nos 1, 3, 5, 7, 9 and 11).
- the vector used is in each case pUCBM21, which was originally developed by Boehringer (SEQ ID Nos 2, 4, 6, 8, 10, 12). However, all other suitable vectors known in the art are also usable.
- the at least one carboxylic acid transporter is encoded by the gene YALI-D-J204 (EMBL-ID: CAG81250; Swiss-Prot ID: Q6C8F4).
- said gene is always also referred to as "JEN4.” It is likewise particularly preferred for said fungus to belong to the genus Yarrowia, particularly preferably to the species Yarrowia lipolytica.
- Y. lipolytica has a total of 6 JEW orthologs. This high number of genes for putative carboxylate transporters reflects the great potential of yeast Y. lipolytica for the production of organic acids, such as. Succinate, malate or fumarate.
- Y. lipolytica is extensively genetically and physiologically characterized, can utilize a broad spectrum of substrates and is tolerant to low pH.
- said fungus contains at least one further genetic modification selected from the group comprising:
- SDH succinate dehydrogenase
- PYC Pyruvatcarboxylase
- ICL isocitrate lyase
- Other candidate genetic modification that can be used in combination with the above modifications are a reduction in the activity or expression of the genes SDH1, SDH3 and / or SDH4, the introduction of a heterologous gene selected from the group coding for phosphoenolpyruvate carboxykinase (PCK1), fumarate reductase and / or fumarase (FUM1), and / or the reduction of the activity or expression of the gene coding for isocitrate dehydrogenase (IDHI) and at least one the genes coding for the mitochondrial dicarboxylate carrier (DIC1) and / or SDH2, and optionally at least one of the genes FUMI, osmotic growth protein (OSMl), malate dehydrogenase (MDH3) and / or citrate synthase (CIT2).
- PCK1 phosphoenolpyruvate carboxykinase
- FUM1 fumarate reductase and / or fumarase
- IDHI isocit
- the reduction of expression can be effected, for example, by a heterologous promoter which is inhibitable by an exogenous factor, preferably a tetracycline-regulated tetO promoter.
- a heterologous promoter which is inhibitable by an exogenous factor, preferably a tetracycline-regulated tetO promoter.
- genes mentioned are identified in the following table, taking as an example the UniProt entries for Saccharomyces cerevisiae. It is understood that the expert can easily find the corresponding genes in other fungal strains, in particular in Yarrowia, based on this information.
- a process for the production of carboxylic acids wherein in the process a fungus strain according to one of the preceding claims is used.
- hexoses such as, for example, glucose or sucrose, or alcohols, for example glycerol
- Glucose and sucrose are particularly suitable because they are inexpensive substrates.
- Glycerol is obtained in large quantities as a waste product, for example in the production of biodiesel and is therefore also a low-cost substrate.
- For glycerol also speaks that its absorption by the fungi is not affected by an impairment of a carboxylic acid transporter.
- the fungal strains are cultured in a medium, and further wherein the oxygen uptake rate (OUR) is adjusted to a range between> 5 and ⁇ 50 mmol 02 / l * h.
- the oxygen uptake rate is adjusted to a range between> 10 and ⁇ 40 mmol 02 / l * h.
- the oxygen uptake rate is adjusted to a range between> 20 and ⁇ 30 mmol 02 / l * h.
- the oxygen uptake rate is controlled to a range between 25 + 3 mmol O 2 / l * h.
- the oxygen input OTR in a fermenter can be influenced by the air aeration rate (1 min -1 ), the stirrer speed (U min -1 ), the pressurization of the fermenter and the gas composition (proportion O 2 in the gas mixture).
- the oxygen uptake rate OUR can be determined from well-known equations based on the known gas composition as well as the amount of gas and the measurement of the oxygen concentration in the exhaust gas.
- FIG. 1 Schematic representation of the expression cassette for exchanging the SDH2
- the SDH2 ORF was fused directly to the respective promoter.
- the pICL1-containing expression cassette was 4.9 kb in size
- the pPOT1 cassette was 3.8 kb
- the GPR1 B cassette was 4.2 kb in size.
- Figure 2 Plasmids pSpIvS-Ura, pSpPS-Ura and pSpGS-U r a m i t d e n
- the selection marker is the marker gene URA3 flanked by the / ox sites.
- Fig. 3 Vector construction of the plasmid p64PIC starting from p64PYCl and p64ICL l. In addition to the desired genes with their own promoter and terminator region, p64PIC contained the URA3-AWe ⁇ ura3d4 as multicopy marker gene and rDNA as integration sequence.
- Fig. 4 PYC and ICL activities of the wild-type strain Y. lipolytica ⁇ 222 and the
- H222 and the transformants H222-AZ7 Tl 1 and T23 in YNB medium were cultured in 150 ml of culture medium in 500 ml Erlenmeyer flasks at 28 ° C. and 220 rpm with 5% glycerol.
- the succinate contents in the culture supernatant were determined by ion chromatography.
- Transformants H222-AZ 10 T l, T5 and T9 in MG medium were cultured in 100 ml of MG medium (growth medium) in 500 ml Erlenmeyer flasks at 28 ° C. and 220 rpm. The sampling for the activity measurement took place after 4 h.
- H222 and the transformants H222-AZ7 TU, H222-AZ8 T3 and H222-AZ10 Tl, T5 and T9 in YNB medium were cultured in 150 ml of culture medium in 500 ml Erlenmeyer flasks at 28 ° C. and 220 rpm with 5% glycerol. The succinate contents in the culture supernatant were determined by ion chromatography.
- Fig. 11 Percent of the organic acids succinate (SA), malate (MA), ⁇ -ketoglutarate (AKG) and fumarate (FA) in the total acid product when cultivating the strains Y. lipolytica H222, H222-AZ8 T3, H222-AZ7 TU and H222-AZ10 Tl, T5 and T9 in YNB medium. Cultivation in YNB medium with 5% glycerol as C source.
- SA organic acids succinate
- MA malate
- AKG ⁇ -ketoglutarate
- FA fumarate
- Fig. 12 Maximum acid production of the MAE1 deleted transformants. Shown was the mean, maximum acid amount of the H222-SW2AMAE1 transformants TF3, TF7 and TF8, as well as the reference strain H222 from 3-fold cultivation in production medium according to Tabuchi et al. (1981).
- AKG ⁇ -ketoglutarate
- FU fumarate
- MA malate
- SUC succinate
- Fig. 13 Vector construction of plasmid p64PYCl starting from p64T.
- Fig. 14 Southern blot analysis confirming the multiple integration of p64PYCl in Y. lipolytica H222-S4.
- the genomic DNA was completely digested with the EcoRV restriction enzyme.
- PYCl a specific probe was used for the PYC1-OKF (2, 1 kb), which was obtained by means of PCR and the primers PYC ORF for and PYC ORF rev.
- the black arrow indicates the 8.9 kb genomic (g) PYCl fragment and the red arrow indicates the 6.2 kb vectorial (v) PYC1 fragment.
- FIG. 15 Kinetics of the specific pyruvate carboxylase activity of the transformants with a multiple integration of the PYCI expression cassette in comparison to the wild-type H222.
- the specific activities were determined during culture in 100 ml of minimal medium containing 1% glucose. The characteristic course of the specific activities resulted from the enzyme activity determinations of three independent cultivations.
- Table la Composition of the YNB culture medium 2. Trace elements YNB
- Table lb Composition of the medium modified according to Tabuchi et al. (1981):
- H222 was selected for the investigation of succinate production. H222 had already proven to be a very good acid producer with respect to citrate or AKG production compared to other Y. lipolytica strains. H222 was cultured in a culture medium optimized for itaconic acid production by Candida strains. As C sources, glucose (10%), glycerol (10%) and sunflower oil (5%) were selected. Cultivation was carried out in 500 ml Erlmeyer flasks without baffling in 100 ml culture medium at 28 ° C. and 220 rpm. When using sunflower oil as C source, the liquid cultures were shaken in 500 ml Erlenmeyer flasks with baffles.
- the preculture was carried out in 50 ml of the same medium and was incubated for 2 to 3 days at 28 ° C and 220 rpm.
- the preculture was harvested by centrifugation (3,500 rpm, 5 min, RT) and taken up in production medium without C source, yeast extract and iron sulfate.
- the main cultures were inoculated with 100 ml each of the production medium at an optical density of 2 OD ml -1 , followed by cultivation at 28 ° C. and 220 rpm for up to 500 h
- the analysis of the concentrations during cultivation Organic acids secreted by Y.
- the lipolytica were obtained by ion chromatography using the Ion Chromatography System ICS-2100 from Dionex (Sunnydale, USA).
- the ion chromatography systems contained the following components: Isocratic pump and conductivity detector IC20, eluent generator EG40, autosampler AS40 / autosampler AS50, self-regenerating suppressor ASRS, separation column IonPac AS 19 (2 x 250 mm) with pre-column IonPac AS 19 (2 x 50 mm), analysis software Chromeleon version 6.8.
- the separation parameters of the separation method are listed in Table 2.
- the resulting aqueous lower phase was transferred to a new reaction vessel and added again with 0.3 ml of n-hexane, shaken and centrifuged again. Again, the aqueous phase was removed and used with appropriate dilution for the ion chromatographic analysis. Since the culture medium used here has not been optimized for Succinat conveyor and cultivating conditions such. B. pH and p0 2 , in Scrissalko Ibenage stab can not be kept permanently stable, was waived in this and in all subsequent cultivation experiments on the calculation of maximum productivity or maximum specific product formation rates.
- H222-S4 The uracil-auxotrophic strain H222-S4 was already present at the beginning of the work (Mauersberger et al., 2001). Additional auxotrophic strains were constructed. Within this project only one uracil auxotrophic strain (H222-SW2) was used. H222-SW2 was generated by deletion of the Ku70 gene whose gene product plays a role in DNA recombination in H222-S4.
- Expression cassettes were constructed which, in addition to the selection marker URA3, contained the corresponding promoter (pICL1, GPR1B or pPOT1) fused to the beginning of the SDH2-OKF and a homologous region of pSDH2 (FIG. 1).
- the selection marker URA3 was flanked by the so-called / ox sites, which enabled a possible later removal of this marker by means of the Cre / ox system.
- the homologous regions from pSDH2 and SDH2-OKF should serve for the homologous integration of this expression cassette.
- the starting plasmid was pUCBM21 ( Figure 2).
- the 5DH2 promoter fragment pSDH2 (569 bp) amplified with the primers pSDH2-fw and pSDH2-rv was first integrated into the NcoI site.
- a 1242 bp fragment of the SDH2 ORF (primer: SDH2-fw and SDH2-rv)
- a 776 bp pICL1 fragment primer: pICL1-fw and pICL1-rv
- were amplified by means of PCR and these were fused by means of overlap PCR (Primer: overlap-fw and overlap-rv).
- this pICL1-SDH2 'fragment was integrated into the vector containing pSDH2, likewise BamH1 and EcoRI.
- this construct was cloned the KpnI and BamRI digest from the plasmid p64PT (Gerber, 1999), the 2.16 kb / / / CZJ fragment between the KpnI and 5 amHI sites, and finally integration the loxR-URA J-ox cassette into this plasmid with the pSDH2-pICL1-SDH2 'cassette digested with XbaI and KpnI.
- the 1.4 kb expression cassette was isolated from plasmid JMP1 13 (Fickers et al., 2003) using XbaI / KpnI digestion. Finally, the 8196 bp plasmid pSpIvS-Ura ( Figure 2) was obtained which contained the expression cassette pSDH2-loxR-URA3-loxP-pICL1-SDH2 'to replace the native SZ ) H2 promoter with the / CZJ promoter.
- pSpPS-Ura plasmid which contained the expression cassette pSDH2-loxR-URA3-loxP-pPOT1-SDH2 'to replace the native 5DH2 promoter with the POT1 promoter.
- This expression cassette could also be isolated from the plasmid by means of ⁇ TspAI / M digestion and used for transformation into the uracil-auxotrophic recipient strain H222-SW2 (MATA ura3-302 ku70A-1572) (Werner 2008).
- GPR1B was isolated from plasmid pTBS1 by PCR (primers: KpnI-pGPR1-fw and pGPR1-SDH2-rv, fragment size: 1971 bp).
- the PCR-derived SDH2'- (838 bp, primer: SDH2-pGPR1-fw, SDH2-MluI-rv) was converted to a 2769 bp size in an overlap PCR with the primers KpnI-pGPR1-fw and SDH2-MluI-rv Construct merged.
- This construct was digested with KpnI and Mlul and ligated to the 4773 bp fragment of pSpIvS-Ura.
- pSpGS-Ura plasmid which contained the expression cassette pSDH2-loxR-URA3-loxP-GPR1B-SDH2 'to replace the native 5DH2 promoter with the Gijii promoter. To verify the sequence, the expression cassettes were sequenced.
- Initial strain was ⁇ 222- ⁇ 2. Furthermore, starting from ⁇ 222- ⁇ 2, strains were constructed in which both PYCl and the isocitrate lyase-encoding gene ICL1 are simultaneously overexpressed.
- ⁇ 222- ⁇ 2 For the construction of a strain ( ⁇ 222- ⁇ 8) in which both the 5DH2 promoter exchanged against the POT1 promoter and the pyruvate carboxylase-encoding gene PYCl are overexpressed, ⁇ 222- ⁇ 2 was used as starting strain. In order to be able to use this for further manipulation, uracil auxotrophy had to be generated in ⁇ 222- ⁇ 2.
- the expression cassette for the replacement of the 5DH2 promoter was constructed such that the marker gene URA3, which is essential for the cell's own uracil synthesis, was flanked by the so-called / ox sites. In order to remove this marker gene and thereby achieve the loss of uracil prototrophy, the so-called Crelox system was used.
- ⁇ 222- ⁇ 2 was transformed with the plasmid pUB4-Cre, which contained both a gene for the Cre recombinase and a hygromycin B resistance-mediating gene.
- the cells were then selected on hygromycin B-containing complete medium and then on minimal medium with or without uracil. Transformants in which recombination of the / ox sites occurred with the help of Cre recombinase could no longer produce uracil due to the loss of URA3 caused by it and therefore could no longer grow on uracil-free medium.
- uracil-auxotrophic transformants From these uracil-auxotrophic transformants, a transformant was selected and used as H222-AZ2U for further work. This was followed by the integrative multicopy plasmid p64PYCl, which contained the PYCl gene with its own promoter and terminator regions coding for pyruvate carboxylase in Y. lipolytica and the URA3 allele ura3d4 as multicopy marker gene and rDNA as integration sequence by means of lithium acetate method (Barth and Gaillardin 1996) into uracil auxotrophic strain H222-AZ2U. There was a selection of the uracil prototrophic transformants uracil-free minimal medium with glucose as C source.
- H222-AZ9 For the construction of a strain (H222-AZ9), in which both the 5DH2 promoter replaced by the POT1 promoter and over-expressed PYC1 and ICL1, was analogous to the construction of H222-AZ8 and a uracil auxotrophic derivative of H222-AZ2 as Initial strain used.
- the plasmid p64PIC to be transformed was constructed by restriction and ligation from the plasmids p64PYCl and p64ICL1 (Kruse et al., 2004). For this purpose, the approximately 4.6 kb Sphl-Fsp AI fragment was isolated from p64ICLI and integrated into the Sphl-FspAI cut vector p64PYCl (FIG. 3).
- the resulting plasmid p64PIC had a size of 15.4 kb and was linearized for transformation in the SacII site.
- the integration was verified by means of PCR or Southern Blot. Two selected transformants were checked for PYC and ICL activity (Table 3) according to Dixon and Kornberg, (1959) and finally cultured in YNB medium.
- HC1 Table 3 Composition of the reaction mixture for determining ICL activity.
- H222-AZ8 T3 - T5
- H222-AZ9 T2 + T3
- FIG. 4 shows the results of these activity measurements.
- Both transformants of H222-AZ8 and H222-AZ9 showed increased PYC activity (2.6-3.7 fold) compared to wild-type H222.
- transformants H222-AZ9 T2 and T3 showed a 24-25 fold increase in ICL activity compared to H222.
- the inventors have conducted studies to characterize the proteins encoded by JEW orthologs in Y. lipolytica. These studies provided clues to the functioning of these JEW gene products as dicarboxylate importers with several specific substrates.
- strains were constructed in which individual JEN genes were deleted. When these strains were cultivated, larger amounts of extracellular succinate were detected in part, especially in the deletion of JEN4.
- a JEN4 deletion cassette (approximately 4.5 kb) was transformed into the uracil-auxotrophic Yarrowia lipolytica strain H222-AZ2U.
- the J £ 7V ⁇ deletion cassette ( Figure 5) contained the promoter and terminator regions of JEN4, with the URA3 flanked by TcR sequences in between (Hübner 2010).
- the deletion cassette was transformed by lithium acetate method. Homologous recombination in the promoter and terminator regions should result in the deletion of JEN4 ( Figure 5).
- Two uracil prototrophic transformants in which the deletion of JEN4 was detected by PCR and Southern blot were isolated. Both transformants were cultured in YNB. The two transformants studied, H222-AZ7 T II and T23, behaved similarly to H222-AZ2 in terms of growth ( Figure 3). Both transformants also produced more succinate than the parent strains H222 and H222-AZ2 ( Figure 6, Table 2).
- Table 4 Maximum succinate levels, volume specific and biomass specific product formation rate of strains H222, H222-AZ7 T1 and T23 in YNB medium.
- the integrative multicopy plasmid p64PYC was constructed by integration of the PCR-amplified ORF of the corresponding gene together with its own promoter and terminator regions of about 1 kb into the recipient vector p64T.
- the pyruvate carboxylase is encoded in Y. lipolytica by a gene ⁇ PYCl) (Flores and Gancedo 2005). Since the region of the ORF of PYCl (3844 bp) together with the associated 1 kb promoter and 0.3 kb terminator region each had a size of 5149 bp, this expression cassette was amplified in two steps in order to introduce any sequence errors decrease by the polymerase.
- the oligonucleotides PYCa for and PYCa rev amplified the 2442 bp region, which included the 1 kb promoter region and part of the ORF of PYCl.
- oligonucleotides PYCa for Pael and PYCb rev added an i g / II site, and the Bgl II site included in the ORF was used for vector integration and fusion of the two fragments.
- the 2442 bp PYCa fragment (promoter region with part of the FC ORF) was digested with Pael and BglII and cloned into the P64 and BglII digested p64T vector.
- the resulting p64PYCla vector was sequenced. Sequencing of the plasmid of clone T22 yielded a defect-free 7C7 ORF, and an error-free promoter region was detected for the plasmid of clone T97. An error-free p64PYCla vector was obtained by the integration of the error-free aeI-i? AmHI promoter region from p64PYCla from clone T97 into the Pael and BamHI digested p64PYCla vector from clone T22. In the resulting p64PYCla vector, the i?
- the additionally detected band at 6.2 kb in the transformants served as evidence for the integration of the multicopy vector p64PYC l. These bands showed an increased intensity compared to the genomic band of the reference strain H222-S4, whereby a multiple integration of the corresponding expression cassette was confirmed.
- the transformants H222-AK1-2, H222-AK1-5, and H222-AK1-7 were selected for further study because of their high vector band intensities.
- the gene-donor effect on pyruvate carboxylase activity was in the strains H222-AK1-2, H222-AK1-5 and H222-AK1-7 examined.
- PYC activity For the determination of PYC activity, all selected transformants were cultured in 100 ml of minimal medium containing 1% glucose. After harvesting a sample of the culture, the yeast cells were disrupted by means of glass beads. The PYC activity was determined in the cell-free extract according to the method of van Urk et al. (1989). The composition of the reaction mixture is listed in the following table. The photometric measurement was carried out at 340 nm.
- the increased gene dose of the PYC-encoding gene showed a positive effect on the specific PYC activities of the strains studied.
- the specific activities for the transformants H222-AK1 -2 and H222-AK1 -7 reached a maximum after 6 h. In contrast, no detectable maximum of the specific enzyme activity was detected for the transformants H222-AK1-5 and for the wild-type H222.
- the transformants H222-AK1-2 and H222-AK1-7 showed the highest specific PYC activities at 0.48 ⁇ 0.04 U / mg and 0.51 ⁇ 0.02 U / mg compared to the other strains investigated, their enzyme activities at 0.42 ⁇ 0. 1 U / mg (H222-AK1-5) and at 0.16 ⁇ 0.06 U / mg (H222) were determined.
- the strain with increased PYC activity showed moderate differences in growth and production behavior.
- the wild type H222 produced a maximum of 3.3 ⁇ 0.02 g L "1 succinate with an average productivity of 5, 4 ⁇ 0.6 mg L " 1 h "1.
- For H 2 2 2-AM3 slightly increased amounts of succinate could be produced of 4.1 ⁇ 0.1 g L "1 .
- H222-AZ10 H222-AZ10
- JEN4 H222-AZ7
- uracil auxotrophy was introduced in H222-AZ7 using FOA-selection.
- FOA 5 'fluororotic acid
- URA3 oritidine 5'-phosphate decarboxylase encoded by URA3.
- 5-fluorouracil is toxic to the cell. Therefore, in the presence of FOA only cells can grow in which no URA3 is present or in which URA3 was removed by recombination of the flanking TcR sequences.
- H222-AZ7 10 3 cells of H222-AZ7 were streaked with glucose on FOA- and uracil-containing minimal medium and the colonies obtained were checked for uracil auxotrophy by means of a punch test. The loss of URA3 was also detected by PCR. From the colonies tested, a uracil auxotrophic was selected (H222-AZ7U) and transformed with the integrative PYCl multicopy vector p64PYCl. After one to two weeks transformants were isolated, which were checked by PCR for the integration of the vector. All tested Transformants were positive. From these positive transformants, 3 were selected and tested for PYC activity. For this purpose, these 3 transformants and the wild type were cultured in minimal medium with glucose. After 4 hours, a sample was taken for the determination of PYC activity and the activity of pyruvate carboxylase was determined.
- the three transformants tested were cultured in YNB medium to examine effects on succinate production.
- FIG. 9 shows growth behavior and succinate production of H222 (wild type) and the new transformants H222-AZ 10 T1, T5 and T9.
- H222-AZ7 TU and H222-AZ 8 T 3 were also included.
- Table 5 The average values from all experiments carried out are summarized in Table 5.
- Table 5 Average maximum succinate levels, volume specific productivities and biomass specific product formation rates of strains H222 (wild-type), H222-AZ10 Tl, T5, T9, H222-AZ8 T3 and H222-AZ7 TU. Cultivation in shake flasks at 28 ° C., 220 rpm in 150 ml of YNB medium with 5% glycerol as C source (+ 3% after 168 h) in two
- Table 6 Maximum product levels of the organic acids malate (MA), ⁇ -ketoglutarate (AKG) and fumarate (FA) when cultivating the strains Y. lipolytica H222, H222-AZ 10 T 1, T5 and T9 in YNB medium. Cultivation in YNB medium at 5%
- the gene of the carboxylate transporter Mael was deleted in Yarrowia lipolytica.
- the deletion cassettes and plasmids used can be found in the table presented at the beginning.
- the deletion strain H222-SW2AMAE1 the deletion of the SpMAE1 homologous gene MAE1, coding for a putative dicarboxylate transporter, was performed.
- Cultures of the H222-SW2AMAE1 transformants 3, 7, and 8 were analyzed for the accumulated organic acids ⁇ -ketoglutarate, fumarate, malate, pyruvate, and succinate in comparison to the parent strain H222.
- the determination of formed biosoluble masses continued to take place.
- the formed dry biomass of the ⁇ 1 transformants when cultivated in 10% glycerol was 40% lower compared to the reference strain H222, but showed little difference in comparison of the transformants with each other. This significant difference in growth may be due to a reduced uptake of the tricarboxylic acid cycle
- Intermediate ⁇ -ketoglutarate, fumarate, malate and succinate result, which are educts of many biosyntheses, such as for amino or fatty acids.
- all transformants showed an increase in the production of the organic acids ⁇ -ketoglutarate, fumarate, malate and succinate studied. On average, a maximum of 30% more AKG, fumarate and succinate and 40% more malate (TF7 only 10%) were formed.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011056290A DE102011056290A1 (en) | 2011-12-12 | 2011-12-12 | MUSHROOMS WITH GENETIC MODIFICATION CONCERNING A CARBONIC ACID TRANSPORTER |
PCT/EP2012/075268 WO2013087714A1 (en) | 2011-12-12 | 2012-12-12 | Fungal strains with genetic modification relating to a carboxylic acid transporter |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2791332A1 true EP2791332A1 (en) | 2014-10-22 |
Family
ID=47458913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12808323.5A Withdrawn EP2791332A1 (en) | 2011-12-12 | 2012-12-12 | Fungal strains with genetic modification relating to a carboxylic acid transporter |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150010973A1 (en) |
EP (1) | EP2791332A1 (en) |
BR (1) | BR112014014082A2 (en) |
DE (1) | DE102011056290A1 (en) |
WO (1) | WO2013087714A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011056297A1 (en) | 2011-12-12 | 2013-06-13 | Thyssenkrupp Uhde Gmbh | Biotechnological production of organic acids by fungal strains, comprises culturing fungal strains in a medium, and controlling oxygen uptake rate |
DE102012101153A1 (en) * | 2012-02-14 | 2013-08-14 | Thyssenkrupp Uhde Gmbh | PROCESS FOR THE BIOTECHNOLOGICAL MANUFACTURE OF ORGANIC ACIDS BY AT LEAST ONE HEFESTAMM |
CN105784908B (en) * | 2016-04-13 | 2017-10-10 | 广东中烟工业有限责任公司 | The chromatography of ions detection method of 6 kinds of anion in cigarette paper |
CN114806913B (en) * | 2022-04-15 | 2023-11-28 | 盛虹控股集团有限公司 | High-yield succinic acid yeast engineered strain with mitochondria-localized reducing TCA pathway and its construction method and application |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003258457A1 (en) | 2002-07-16 | 2004-02-09 | Technische Universitat Dresden | Method for the biotechnological production of citric acid by means of a genetically-modified yeast yarrowia lipolytica |
US20110039327A1 (en) * | 2007-05-18 | 2011-02-17 | Aaron Adriaan Winkler | Organic acid production by fungal cells |
CN102016053A (en) | 2008-02-15 | 2011-04-13 | 帝斯曼知识产权资产管理有限公司 | Process for the production of a dicarboxylic acid |
-
2011
- 2011-12-12 DE DE102011056290A patent/DE102011056290A1/en not_active Ceased
-
2012
- 2012-12-12 BR BR112014014082A patent/BR112014014082A2/en not_active IP Right Cessation
- 2012-12-12 WO PCT/EP2012/075268 patent/WO2013087714A1/en active Application Filing
- 2012-12-12 US US14/364,969 patent/US20150010973A1/en not_active Abandoned
- 2012-12-12 EP EP12808323.5A patent/EP2791332A1/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2013087714A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20150010973A1 (en) | 2015-01-08 |
BR112014014082A2 (en) | 2019-09-24 |
DE102011056290A1 (en) | 2013-06-13 |
WO2013087714A1 (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Metabolic engineering of an acid-tolerant yeast strain Pichia kudriavzevii for itaconic acid production | |
EP2744896B1 (en) | Pichia ciferrii cells and use thereof | |
AT501955A1 (en) | MUTED AOX1 PROMOTERS | |
JP2018525018A (en) | Method for producing phytosphingosine or sphinganine | |
KR20140033002A (en) | A yeast cell for the production of terpenes and uses thereof | |
EP3290518A1 (en) | Novel gene targeting method | |
EP3455362A1 (en) | Mutant yeast strains with enhanced production of erythritol or erythrulose | |
EP4438717A1 (en) | Acid-resistant yeast strain for high-yield production of succinic acid, and construction method therefor and use thereof | |
WO2013087714A1 (en) | Fungal strains with genetic modification relating to a carboxylic acid transporter | |
JP2010075171A (en) | High-efficiency method for producing lactic acid by candida utilis | |
WO2015189352A1 (en) | Improved lipid accumulation in yarrowia lipolytica strains by overexpression of hexokinase and new strains thereof | |
Štafa et al. | Novel Approach in the Construction of Bioethanol-Producing Saccharomyces cerevisiae Hybrids § | |
WO2006136311A1 (en) | Metabolic engineering of q10 production in yeasts of the genus sporidiobolus | |
EP4095230A1 (en) | Genetically modified yeast for the biotechnological production of succinic acid from glycerol | |
US20120045803A1 (en) | Method for production of substance in candida utilis using xylose as carbon source | |
JP2013021940A (en) | Method for producing gene knockout yeast | |
EP4133091A2 (en) | A universal gene expression system for expressing genes in oleaginous yeasts | |
WO2021062082A1 (en) | System and method for increased alcohol tolerance and production in yeast | |
EP1280893B1 (en) | Method for the production of proteins in a yeast of the genus arxula and suitable promoters | |
WO2010095751A1 (en) | High-efficiency lactic acid manufacturing method using candida utilis | |
DE10333144B4 (en) | Process for the biotechnological production of citric acid with a genetically modified yeast Yarrowia lipolytica | |
US9976148B2 (en) | Yeast terminator and use therefor | |
Štafa et al. | Novi pristup u konstrukciji hibridnih sojeva kvasca Saccharomyces cerevisiae za proizvodnju bioetanola | |
CN108866050B (en) | Efficient genetic engineering vector | |
AT526405A1 (en) | Synthetic formolase pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140528 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KRETZSCHMAR, ANNE Inventor name: WAENGLER, ISABEL Inventor name: OTTO, CHRISTINA Inventor name: AURICH, ANDREAS Inventor name: MUELLER, ROLAND ARNO Inventor name: BARTH, GEROLD Inventor name: HOLZ, MARTINA |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160314 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170923 |